/KROS
KROS Stock - Keros Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$20.26+0.65%
+$0.13 (+0.65%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+402.8%upside
Target: $101.87
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KROS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.06 – $20.46
TARGET (TP)$101.86
STOP LOSS$18.64
RISK/REWARD1:50.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.90
52W High$22.55
52W Low$9.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.55M | $151,000 | N/A | $20.10M | N/A |
| Gross Profit | $3.55M | $151,000 | N/A | $20.10M | $-605,000 |
| Gross Margin | 100.0% | 100.0% | N/A | 100.0% | N/A |
| Operating Income | $-210,833,000 | $-169,941,000 | $-114,790,000 | $-56,373,000 | $-46,657,000 |
| Net Income | $-187,353,000 | $-152,992,000 | $-104,679,000 | $-58,744,000 | $-45,361,000 |
| Net Margin | -5277.5% | -101319.2% | N/A | -292.3% | N/A |
| EPS | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 |
Company Overview
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
67%
Hold / Neutral
6
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
12 Bullish6 Neutral/Bearish
Price Targets
$63
Average Target
↑ 211.8% Upside
Now
$15
Low
$63
Average
$102
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $26 |
| June 10th 2025 | BofA Securities | Downgrade | Neutral | $18 |
| January 21st 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| January 17th 2025 | Wedbush | Downgrade | Neutral | $15 |
| December 16th 2024 | Oppenheimer | Reiterated | Outperform | $63← $102 |
| December 16th 2024 | Guggenheim | Downgrade | Neutral | - |
| December 13th 2024 | H.C. Wainwright | Reiterated | Buy | $47← $100 |
| December 12th 2024 | TD Cowen | Downgrade | Hold | - |
| December 12th 2024 | William Blair | Downgrade | Market Perform | - |
| December 12th 2024 | BTIG Research | Downgrade | Neutral | - |
| November 5th 2024 | Jefferies | Initiation | Buy | - |
| October 24th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| September 23rd 2024 | Guggenheim | Initiation | Buy | $96 |
| June 25th 2024 | Oppenheimer | Initiation | Outperform | $102 |
Earnings History & Surprises
KROSBeat Rate
61%
Last 18 quarters
Avg Surprise
+2026.5%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-0.18
Q4 2025
EPS Surprise History
Q1 24
+2.9%
$-1.34vs$-1.38
Q2 24
+7.6%
$-1.21vs$-1.31
Q3 24
-1.6%
$-1.25vs$-1.23
Q4 24
-11.9%
$-1.41vs$-1.26
Q1 25
+16.2%
$-1.14vs$-1.36
Q2 25
+36300.0%
$3.62vs$-0.01
Q3 25
+33.3%
$-0.76vs$-1.14
Q4 25
+83.8%
$-0.18vs$-1.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.49 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.11 | $-0.18 | +83.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-1.14 | $-0.76 | +33.3% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.01 | $3.62 | +36300.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-1.36 | $-1.14 | +16.2% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.26 | $-1.41 | -11.9% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-1.23 | $-1.25 | -1.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-1.31 | $-1.21 | +7.6% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-1.38 | $-1.34 | +2.9% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-1.34 | $-1.33 | +0.7% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-1.34 | $-1.27 | +5.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.13 | $-1.26 | -11.5% | ✗ MISS |
Q1 2023 | Mar 3, 2023 | $-1.12 | $-1.09 | +2.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.26 | $-0.92 | +27.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-1.07 | $-1.13 | -5.6% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.86 | $-1.01 | -17.4% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-0.94 | $-0.30 | +68.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.72 | $-0.87 | -20.8% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.66 | $-0.67 | -1.5% | ✗ MISS |
Latest News
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19
➖ NeutralBenzinga•Nov 28, 2025, 05:08 PM
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27
📈 PositiveBenzinga•Nov 12, 2025, 04:30 PM
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23
➖ NeutralBenzinga•Nov 11, 2025, 02:32 PM
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16
➖ NeutralBenzinga•Nov 6, 2025, 01:35 PM
Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:04 PM
Keros Therapeutics Announced That It Has Commenced A Cash Tender Offer To Repurchase Up To $194.4M Of Shares Of The Company's Common Stock At A Purchase Price Of $17.75 Per Share
📈 PositiveBenzinga•Oct 20, 2025, 10:04 AM
Keros jumps on plan to return $375M in excess capital
📈 PositiveSeeking Alpha•Oct 15, 2025, 10:49 AM
Keros Therapeutics Plans To Commence Tender Offer To Repurchase Up To $194M Of Additional Shares At $17.75/Shr In Cash
📈 PositiveBenzinga•Oct 15, 2025, 10:36 AM
Keros Therapeutics To Repurchase $181M In Shares From ADAR1 And Pontifax Under $375M Capital Return Plan; Deal Set To Close October 15
📈 PositiveBenzinga•Oct 15, 2025, 10:34 AM
Keros Therapeutics Highlights Presentation Of KER-065 Data At American Society of Bone and Mineral Research 2025 Annual Meeting On Sept. 6
➖ NeutralBenzinga•Sep 8, 2025, 12:05 PM
ADAR1 Capital Urges Keros Therapeutics Board To Engage On Strategy And Capital Return, Warns Of Potential Board Changes
📉 NegativeBenzinga•Aug 21, 2025, 12:36 PM
Keros Therapeutics Reveals The FDA Granted Orphan Drug Designation For KER-065 For The Treatment Of Duchenne Muscular Dystrophy
📈 PositiveBenzinga•Aug 20, 2025, 01:50 PM
Frequently Asked Questions about KROS
What is KROS's current stock price?
Keros Therapeutics, Inc. (KROS) is currently trading at $20.26 per share. The stock has moved +0.65% today.
What is the analyst price target for KROS?
The average analyst price target for KROS is $101.86, based on 1 analyst.
What sector is Keros Therapeutics, Inc. in?
Keros Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KROS's market cap?
Keros Therapeutics, Inc. has a market capitalization of $0.82 billion, making it a small-cap company.
Does KROS pay dividends?
No, Keros Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
NAGE
Niagen Bioscience Inc
$6.52
Mkt Cap: $0.5B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to KROS for comparison